SCHEMBL6793009

SCHEMBL6793009

c1coc(-c2[nH]nc3c2CCc2cnccc2-3)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.39
CYP1A2 P05177 3/20 0.38
CYP2E1 P05181 3/20 0.38
CYP3A4 P08684 3/20 0.38
CYP2C8 P10632 3/20 0.38
CYP2A6 P11509 3/20 0.38
CYP2C9 P11712 3/20 0.38
CYP2B6 P20813 3/20 0.38
CYP2C19 P33261 3/20 0.38
CYP2D6 P10635 2/20 0.38
ADORA2A P29274 5/20 0.37
ADORA2B P29275 5/20 0.37
ADORA1 P30542 5/20 0.37
FYN P06241 2/20 0.36
CDK2 P24941 2/20 0.35
CDK1 P06493 1/20 0.35
KDM4E B2RXH2 1/20 0.34
USP2 O75604 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11830989 0.84 GSR (0.47) NPC1FYNCDK2CDK1KDM4E
SCHEMBL6800060 0.75 AURKA (0.46) NPC1CYP2C8CYP2C9CDK2CDK1
SCHEMBL11859697 0.75 KDR (0.56) FYNCDK2CDK1KDM4EUSP2
SCHEMBL6794554 0.70 CHRNB2 (0.37) NPC1CDK2CDK1KDM4EHSD17B10
SCHEMBL6793634 0.69 CHRNB2 (0.36) NPC1CDK2CDK1KDM4EHSD17B10
SCHEMBL6794364 0.69 CHRNB2 (0.36) NPC1CYP1A2CDK2CDK1KDM4E
SCHEMBL6255841 0.69 HSD17B10 (0.55) ADORA2AADORA2BADORA1KDM4EALDH1A1
SCHEMBL6787408 0.69 MEN1 (0.58) NPC1CYP2C8CYP2C9CDK2KDM4E
SCHEMBL6792954 0.69 NPC1 (0.44) NPC1CDK2KDM4EHSD17B10CCNE2
SCHEMBL8063320 0.68 NPC1 (0.65) NPC1CDK2CDK1GSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040127492-A1 Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 PHARMACIA CORPORATION 2004-07-01 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127492-A1 Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 MKNK2, MAPKAPK2, MAP3K2 NPC1 4242/4885CYP1A2 1087/4885CYP2E1 2323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.